Baudax Bio files for bankruptcy a year after halting sales of its pain medicine Anjeso

[ad_1]

In December, Baudax Bio filed a notice with the SEC stating that its financial struggles “raise substantial doubt about [the company’s] ability to continue as a going concern.”

[ad_2]

John George

Source link